The Chennai-based global pharma major Orchid Chemicals & Pharmaceuticals Ltd announced that it had obtained approval from US FDA for its Abbreviated New Drug Application or ANDA for Naratriptan tablets in the strengths of 1mg and 2.5mg.
Naratriptan tablets are the generic equivalent of GlaxoSmithKline Pharmaceutical's Amerge tablets and is used to treat migraine headaches.
The US market size for the product is around $30 million, as per 2011 sales.
This product is part of the strong oral non-antibiotic formulations pipeline for Orchid and will be manufactured at its FDA approved plant located in Chennai.
Orchid would be launching this product in the U.S. during this quarter, an official said.
At the BSE, Orchid Chemicals & Pharmaceuticals shares are currently trading at Rs.175.85, up 0.86 percent from the previous close.
For comments and feedback: editorial@rttnews.com